Description
Principle of the Assay::This kit was based on sandwich enzyme-linked immune-sorbent assay technology. Anti-CK-MB monoclonal antibody was pre-coated onto 96-well plates. And the biotin conjugated anti-CK-MB monoclonal antibody was used as detection antibody. The standards, test samples and biotin conjugated detection antibody were added to the wells subsequently, and wash with wash buffer. Avidin-Biotin-Peroxidase Complex was added and unbound conjugates were washed away with wash buffer. TMB substrates were used to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that changed into yellow after adding acidic stop solution. The density of yellow is proportional to the CK-MB amount of sample captured in plate. Read the O.D. absorbance at 450nm in a microplate reader, and then the concentration of CK-MB can be calculated.
Background/Introduction: Creatine kinase isoenzyme-MB (CK-MB) is a biomarker for detecting myocardial injury. It is a simple, widely available, and useful biomarker for predicting adverse in-hospital clinical outcomes in pulmonary embolism. The encoded protein reversibly catalyzes the transfer of phosphate between ATP and various phosphogens such as creatine phosphate. It acts as a homodimer in striated muscle as well as in other tissues, and as a heterodimer with a similar brain isozyme in heart. The CK-MB-to-total-CK ratio is an easily available indicator and could be clinically utilized as a primary screening tool for cancer. Higher ratio of CK-MB-to-total-CK was specifically associated with certain malignancies, like colorectal cancer, lung cancer and hepatocellular carcinoma, as well as some cancer-associated status factors such as advanced stage and liver metastasis